Hancock Whitney Corp Has $13.83 Million Stock Position in Edwards Lifesciences Corp (NYSE:EW)

Hancock Whitney Corp reduced its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 2.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 72,259 shares of the medical research company’s stock after selling 2,078 shares during the quarter. Hancock Whitney Corp’s holdings in Edwards Lifesciences were worth $13,825,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. FTB Advisors Inc. bought a new position in shares of Edwards Lifesciences during the first quarter valued at approximately $25,000. Executive Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $25,000. Sontag Advisory LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Field & Main Bank purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $34,000. Finally, Lindbrook Capital LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $27,000. 82.00% of the stock is currently owned by institutional investors.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction on Monday, April 29th. The shares were sold at an average price of $174.73, for a total value of $5,731,144.00. Following the transaction, the chief executive officer now directly owns 75,926 shares in the company, valued at $13,266,549.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Catherine M. Szyman sold 1,474 shares of Edwards Lifesciences stock in a transaction on Monday, April 15th. The shares were sold at an average price of $192.00, for a total transaction of $283,008.00. Following the completion of the transaction, the vice president now owns 21,132 shares in the company, valued at $4,057,344. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 133,468 shares of company stock valued at $23,822,542. Corporate insiders own 1.63% of the company’s stock.

Edwards Lifesciences stock traded down $0.75 during trading on Monday, hitting $183.99. The company had a trading volume of 1,841,100 shares, compared to its average volume of 1,328,002. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.19. Edwards Lifesciences Corp has a 1-year low of $134.53 and a 1-year high of $197.86. The stock has a market cap of $38.73 billion, a PE ratio of 39.15, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. The company has a 50 day simple moving average of $179.88.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.23 by $0.09. The company had revenue of $993.00 million during the quarter, compared to analysts’ expectations of $989.87 million. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The firm’s revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.22 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corp will post 5.29 earnings per share for the current year.

A number of analysts have weighed in on the company. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $199.00 target price for the company in a report on Thursday, May 9th. Deutsche Bank upped their price target on Edwards Lifesciences from $164.00 to $184.00 and gave the stock a “hold” rating in a research report on Wednesday, April 24th. Jefferies Financial Group upped their price target on Edwards Lifesciences from $195.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. BMO Capital Markets upped their price target on Edwards Lifesciences to $204.00 and gave the stock an “outperform” rating in a research report on Friday, March 22nd. Finally, BTIG Research reissued a “hold” rating on shares of Edwards Lifesciences in a research report on Wednesday, April 24th. Two analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $188.10.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: Trading Options- What is a Strangle?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.